ClinicalTrials.gg
CompletedNCT01426763Updated Jul 19, 2021Results posted

A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase

A Phase 2 interventional study of CINRYZE with rHuPH20 in Hereditary Angioedema, sponsored by Shire. Completed at 4 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-07-19.

Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing C1 esterase inhibitor (human) in Angioedemas, Hereditary — 1 open to participants now, 1 under way, none of them phase 3. C1 esterase inhibitor (human) · Angioedemas, Hereditary.

Enrollment
10th of 11
12 · median 32
Started
2011
the only one that year
Phase 2
8 of 11
1 open now
Registered
7th of 11
by date
Lead sponsor
5 of 11
Shire

Among the 11 studies testing C1 esterase inhibitor (human) in Angioedemas, Hereditary, this one is the 10th largest by enrollment, is the only one that started in 2011, is one of 8 in phase 2, and was the 7th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

1 of the 11 studies testing C1 esterase inhibitor (human) in Angioedemas, Hereditary is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About C1 esterase inhibitor (human)

C1 esterase inhibitor (human): first FDA approval 2008 (Cinryze), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing C1 esterase inhibitor (human) in Angioedemas, Hereditary, or all of them as a file.
02

Study summary

The objectives of the study are to:

  1. Evaluate the safety and tolerability of subcutaneously administered CINRYZE with recombinant human hyaluronidase (rHuPH20) in subjects with hereditary angioedema (HAE) who previously participated in CINRYZE Study 0624-200 (NCT01095497)
  2. Characterize the pharmacokinetics and pharmacodynamics of subcutaneously administered CINRYZE with rHuPH20
  3. Assess the immunogenicity of CINRYZE following subcutaneous (SC) administration of CINRYZE with rHuPH20
03

Conditions studied

  • Hereditary Angioedema

Keywords

  • HAE
  • C1 esterase inhibitor
  • C1 INH
  • Subcutaneous
  • hyaluronidase
  • rHuPH20
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible for this protocol, a subject must:

  1. Provide /assent, as appropriate.
  2. Have previously participated in CINRYZE Study 0624-200 and completed the subcutaneous therapy period in that study.
  3. During the 3 consecutive months prior to screening, have a history of less than 1 HAE attack per month (average) that required treatment with C1 INH therapy or other blood products.
  4. Agree to avoid his/her known HAE triggers during the study to the best of his/her ability.

Exclusion criteria

Exclusion Criteria:

To be eligible for this protocol, a subject must not:

  1. Have received C1 INH therapy or any blood products for treatment or prevention of an HAE attack within 14 days prior to the first dose of study drug.
  2. Have received any ecallantide (Kalbitor), icatibant (Firazyr), or antifibrinolytics (e.g., tranexamic acid) within 14 days prior to the first dose of study drug.
  3. Have any change (start, stop, or change in dose) in androgen therapy (e.g., danazol, oxandrolone, stanozolol, testosterone) within 14 days prior to the first dose of study drug.
  4. If female, have started taking or changed the dose of any hormonal regimen or hormone replacement therapy (i.e., estrogen/progestin containing products) within 3 months prior to the first dose of study drug.
  5. Have a history of abnormal blood clotting.
  6. Have a history of allergic reaction to products containing C1 INH or other blood products.
  7. Have a known allergy to hyaluronidase or any other ingredient in rHuPH20.
  8. Be pregnant or breastfeeding.
  9. Have received an study drug within 30 days prior to the first dose of study drug.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    SC CINRYZE with rHuPH20 Dose Level 1

    Subcutaneous injection of 1000 Units of CINRYZE with 20,000 Units of rHuPH20 twice weekly for two weeks

    Biological: CINRYZE with rHuPH20

  • Experimental
    SC CINRYZE with rHuPH20 Dose Level 2

    Subcutaneous injection of 2000 Units of CINRYZE with 40,000 Units of rHuPH20 twice weekly for two weeks

    Biological: CINRYZE with rHuPH20

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Adverse Events, Number of Participants With Local Injection Site Reactions, and Number of Participants Who Discontinue Study Drug or Withdraw From the Study

    Time frame: 18 days

Secondary outcomes

  1. Mean Change C1 Inhibitor (C1INH)

    Mean Change in Baseline in Observed Plasma Concentration of C1 Inhibitor (C1INH) Antigen. Baseline-corrected concentrations were derived by subtracting the observed pre-dose concentrations on Day 1 of each treatment period from each observed concentration.

    Time frame: 18 days

  2. Mean Change C4 Compliment

    Mean Change in Baseline in Observed Plasma Concentration of C4 Compliment. Baseline-corrected concentrations were derived by subtracting the observed pre-dose concentrations on Day 1 of each treatment period from each observed concentration.

    Time frame: 18 days

  3. Number of Subjects With C1 INH Antibodies

    Time frame: Day 1 (pre-dose), Day 18 (168 h post Dose 4), and 30 (±2) days after the last dose of study drug (Dose 4)

07

Results

Posted Jan 4, 2013

Participant flow

Participant flow — Overall Study
MilestoneSubcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1SC CINRYZE With rHuPH20 Dose Level 2
Started66
Completed66
Not completed00

Outcome measures

PrimaryIncidence and Severity of Adverse Events, Number of Participants With Local Injection Site Reactions, and Number of Participants Who Discontinue Study Drug or Withdraw From the Study
Time frame:
18 days
Reported as:
Number · participants
Incidence and Severity of Adverse Events, Number of Participants With Local Injection Site Reactions, and Number of Participants Who Discontinue Study Drug or Withdraw From the Study
participantsSubcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1SC CINRYZE With rHuPH20 Dose Level 2
Number of participants with adverse events65
Number of participants with injection site reactions65
Number of participants who discontinued study drug00
Number of participants who withdrew from the study00
SecondaryMean Change C1 Inhibitor (C1INH)

Mean Change in Baseline in Observed Plasma Concentration of C1 Inhibitor (C1INH) Antigen. Baseline-corrected concentrations were derived by subtracting the observed pre-dose concentrations on Day 1 of each treatment period from each observed concentration.

Time frame:
18 days
Reported as:
Mean · g/L
Mean Change C1 Inhibitor (C1INH)
g/LSubcutaneous (SC) With Recombinant Human Hyaluronidase ph20 (rHuPH20) CYNRYZE Dose 1SC CINRYZE With rHuPH20 Dose Level 2
0 Hour (h)0.0248 ± 0.05650.00483 ± 0.00904
1 hour (h) post Dose 10.0273 ± 0.0650.00383 ± 0.00417
2 h post Dose 10.0302 ± 0.06370.008 ± 0.0123
3 h post Dose 10.0275 ± 0.06020.0095 ± 0.00729
4 h post Dose 10.0382 ± 0.06520.011 ± 0.00537
6 h post Dose 10.0398 ± 0.05990.020 ± 0.00678
8 h post Dose 10.0455 ± 0.06240.031 ± 0.0154
24 h post Dose 10.0625 ± 0.07280.0612 ± 0.0212
48 h post Dose 10.0665 ± 0.07490.0603 ± 0.0213
Pre-Dose 20.0243 ± 0.02340.0507 ± 0.0168
1 h post Dose 20.0387 ± 0.07490.00833 ± 0.00852
120 h post Dose 10.020 ± 0.008830.0388 ± 0.0132
Pre-Dose 30.0288 ± 0.06440.00833 ± 0.0095
1 h post Dose 30.00217 ± 0.002710.004 ± 0.00405
Pre-Dose 40.006 ± 0.01190.0128 ± 0.00854
1 h post Dose 40.0193 ± 0.0120.033 ± 0.0196
2 h post Dose 40.0233 ± 0.01260.0377 ± 0.021
3 h post Dose 40.0238 ± 0.0120.0333 ± 0.0163
4 h post Dose 40.0257 ± 0.01420.037 ± 0.0215
6 h post Dose 40.0298 ± 0.01240.039 ± 0.025
8 h post Dose 40.0354 ± 0.01180.0397 ± 0.0157
24 h post Dose 40.0347 ± 0.0180.0623 ± 0.0207
48 h post Dose 40.0273 ± 0.01710.0562 ± 0.00906
72 h post Dose 40.0167 ± 0.01850.046 ± 0.0106
120 h post Dose 40.0165 ± 0.02140.0157 ± 0.00797
168 h post Dose 40.00933 ± 0.02010.0382 ± 0.0935
SecondaryMean Change C4 Compliment

Mean Change in Baseline in Observed Plasma Concentration of C4 Compliment. Baseline-corrected concentrations were derived by subtracting the observed pre-dose concentrations on Day 1 of each treatment period from each observed concentration.

Time frame:
18 days
Reported as:
Mean · mg/L
Mean Change C4 Compliment
mg/LSubcutaneous (SC) With Recombinant Human Hyaluronidase ph20 (rHuPH20) CYNRYZE Dose 1SC CINRYZE With rHuPH20 Dose Level 2
0 Hour (h)9.00 ± 15.413.3 ± 14.4
1 hour (h) post Dose 111.0 ± 14.310.3 ± 21.4
2 h post Dose 111.3 ± 13.811.0 ± 18.7
3 h post Dose 110.2 ± 11.711.5 ± 17.6
4 h post Dose 111.5 ± 13.613.2 ± 16.8
6 h post Dose 115.7 ± 14.214.0 ± 18.1
8 h post Dose 116.3 ± 16.622.5 ± 29.1
24 h post Dose 125.0 ± 15.630.5 ± 19.5
48 h post Dose 137.4 ± 23.149.8 ± 24.3
Pre-Dose 224.3 ± 14.553.3 ± 23.2
1 h post Dose 237.5 ± 21.653.2 ± 22.6
120 h post Dose 135.6 ± 22.670.8 ± 28.4
Pre-Dose 329.0 ± 19.166.3 ± 47.0
1 h post Dose 332.5 ± 18.769.3 ± 50.5
Pre-Dose 432.0 ± 18.462.5 ± 54.2
1 h post Dose 430.2 ± 18.857.3 ± 53.7
2 h post Dose 433.3 ± 24.559.7 ± 52.5
3 h post Dose 434.3 ± 17.953.3 ± 46.2
4 h post Dose 434.8 ± 22.963.3 ± 56.5
6 h post Dose 436.3 ± 21.659.7 ± 46.4
8 h post Dose 433.6 ± 20.356.5 ± 48.4
24 h post Dose 437.8 ± 23.064.7 ± 52.4
48 h post Dose 433.0 ± 22.465.7 ± 47.0
72 h post Dose 423.3 ± 20.672.2 ± 57.5
120 h post Dose 416.8 ± 15.558.7 ± 46.4
168 h post Dose 419.0 ± 18.444.8 ± 46.0
SecondaryNumber of Subjects With C1 INH Antibodies
Time frame:
Day 1 (pre-dose), Day 18 (168 h post Dose 4), and 30 (±2) days after the last dose of study drug (Dose 4)
Reported as:
Number · Participants
Number of Subjects With C1 INH Antibodies
ParticipantsSubcutaneous (SC) With Recombinant Human Hyaluronidase ph20 (rHuPH20) CYNRYZE Dose 1SC CINRYZE With rHuPH20 Dose Level 2
Day 1 (pre-dose)00
Day 18 (168 h post Dose 4)00
30 (±2) days after the last dose of study drug (Dose 4)00

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1—0/6 (0%)6/6 (100%)
SC CINRYZE With rHuPH20 Dose Level 2—0/6 (0%)5/6 (83.3%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventSubcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1SC CINRYZE With rHuPH20 Dose Level 2
Injection site erythemaGeneral disorders5/65/6
Injection site painGeneral disorders4/61/6
Injection site swellingGeneral disorders2/60/6
Injection site hemorrhageGeneral disorders1/60/6
Injection site indurationGeneral disorders0/61/6
Injection site edemaGeneral disorders1/60/6
Injection site pruritusGeneral disorders1/60/6
Upper respiratory tract infectionInfections and infestations1/60/6
Urinary tract infectionInfections and infestations0/61/6
Pain in extremityMusculoskeletal and connective tissue disorders0/61/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1SC CINRYZE With rHuPH20 Dose Level 2Total
Mean31.5 ± 7.7933.7 ± 10.2732.6 ± 8.76
Sex: Female, Male
Sex: Female, Male(Participants)Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1SC CINRYZE With rHuPH20 Dose Level 2Total
Female347
Male325
08

Study locations

4 sites
  • ViroPharma Investigational Site
    Scottsdale, Arizona 85251, United States
  • ViroPharma Investigational Site
    Walnut Creek, California 94598, United States
  • ViroPharma Investigational Site
    Atlanta, Georgia 30342, United States
  • ViroPharma Investigational Site
    Dallas, Texas 75231, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2011 to primary completion in Nov 2011, 2 months.

Results were first posted in Jan 2013, 1 year 1 month after primary completion.

Of 17 phase 2 interventional studies under Angioedemas, Hereditary, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2011
First posted
Aug 31, 2011
StartActual
Sep 12, 2011
Primary completionActual
Nov 28, 2011
CompletionActual
Nov 28, 2011
Results first posted
Jan 4, 2013
Last update
Jul 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01426763
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Aug 31, 2011
Start date
Sep 12, 2011
Primary completion
Nov 28, 2011
Completion
Nov 28, 2011
Results posted
Jan 4, 2013
Last update
Jul 19, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: C1 esterase inhibitor (human) · Hyaluronidase (human recombinant)

Start the discussion